AIM: The mucoprotective agents, sofalcone and polaprezinc have anti-Helicobacter pylori ( H pylori)activities. We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole,amoxicil...AIM: The mucoprotective agents, sofalcone and polaprezinc have anti-Helicobacter pylori ( H pylori)activities. We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole,amoxicillin and clarithromycin for Helicobacter pylori infection.METHODS: One hundred and sixty-five consecutive outpatients with peptic ulcer and H pylori infection were randomly assigned to one of the following three groups and medicated for 7 d. Group A: triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily). Group B: sofalcone (100 mg thrice daily) plus the triple therapy.Group C: polaprezinc (150 mg twice daily) plus the triple therapy. Eradication was considered successful if 13C-urea breath test was negative at least 4 wk after cessation of eradication regimens or successive famotidine in the cases of active peptic ulcer.RESULTS: On intention-to-treat basis, H pyloricure wasachieved in 43 of 55 (78.2%) patients, 47 of 54 (87.0%)and 45 of 56 (80.4%) for the groups A, B and Crespectively. Using per protocol analysis, the eradication rates were 81.1% (43/53), 94.0% (47/50) and 84.9% (45/53) respectively. There was a significant difference in the cure rates between group A and B. Adverse events occurred in 10, 12 and 11 patients, from groups A, B and C respectively, but the events were generally mild.CONCLUSION: The addition of sofalcone, but not polaprezinc, significantly increased the cure rate of H pylori infection when combined with the rabeprazole-amoxicillinclarithromycin regimen.展开更多
The title compound,（E）-ethyl 2-（5-（3-methyl-2-butenyloxy）-2-（3-（4-（3-methyl-2-butenyloxy）phenyl） acryloyl） phenoxy）acetate（1）,has been synthesized and characterized by FT-IR and 1H-NMR spectroscopy,ESI-M...The title compound,（E）-ethyl 2-（5-（3-methyl-2-butenyloxy）-2-（3-（4-（3-methyl-2-butenyloxy）phenyl） acryloyl） phenoxy）acetate（1）,has been synthesized and characterized by FT-IR and 1H-NMR spectroscopy,ESI-MS,and X-ray single-crystal diffraction.FT-IR,1H-NMR and ESI-MS confirm the functional groups,particularly the ethyl groups in the ester moiety,of the compound.The single-crystal X-ray diffraction has revealed a monoclinic structure,space group P21/n with a = 14.6832（14）,b = 7.7581（7）,c = 23.075（2）,β = 101.670（2）o,V = 2574.2（4） ？3,Z = 4,Dc = 1.235 g/cm,μ = 0.085 mm-1,and F（000） = 1024.The skeleton of chalcone in the molecular structure is coplanar.展开更多
文摘AIM: The mucoprotective agents, sofalcone and polaprezinc have anti-Helicobacter pylori ( H pylori)activities. We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole,amoxicillin and clarithromycin for Helicobacter pylori infection.METHODS: One hundred and sixty-five consecutive outpatients with peptic ulcer and H pylori infection were randomly assigned to one of the following three groups and medicated for 7 d. Group A: triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily). Group B: sofalcone (100 mg thrice daily) plus the triple therapy.Group C: polaprezinc (150 mg twice daily) plus the triple therapy. Eradication was considered successful if 13C-urea breath test was negative at least 4 wk after cessation of eradication regimens or successive famotidine in the cases of active peptic ulcer.RESULTS: On intention-to-treat basis, H pyloricure wasachieved in 43 of 55 (78.2%) patients, 47 of 54 (87.0%)and 45 of 56 (80.4%) for the groups A, B and Crespectively. Using per protocol analysis, the eradication rates were 81.1% (43/53), 94.0% (47/50) and 84.9% (45/53) respectively. There was a significant difference in the cure rates between group A and B. Adverse events occurred in 10, 12 and 11 patients, from groups A, B and C respectively, but the events were generally mild.CONCLUSION: The addition of sofalcone, but not polaprezinc, significantly increased the cure rate of H pylori infection when combined with the rabeprazole-amoxicillinclarithromycin regimen.
基金Supported by the Jiangxi Provincial Department of Education (GJJ08433)Jiangxi Provincial Department of Science and Technology (2008ZD06100)
文摘The title compound,（E）-ethyl 2-（5-（3-methyl-2-butenyloxy）-2-（3-（4-（3-methyl-2-butenyloxy）phenyl） acryloyl） phenoxy）acetate（1）,has been synthesized and characterized by FT-IR and 1H-NMR spectroscopy,ESI-MS,and X-ray single-crystal diffraction.FT-IR,1H-NMR and ESI-MS confirm the functional groups,particularly the ethyl groups in the ester moiety,of the compound.The single-crystal X-ray diffraction has revealed a monoclinic structure,space group P21/n with a = 14.6832（14）,b = 7.7581（7）,c = 23.075（2）,β = 101.670（2）o,V = 2574.2（4） ？3,Z = 4,Dc = 1.235 g/cm,μ = 0.085 mm-1,and F（000） = 1024.The skeleton of chalcone in the molecular structure is coplanar.
